tradmap

IPSC Century Therapeutics, Inc.

$2.08 -1.89%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Century Therapeutics, Inc. (IPSC) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $377 million. Shares last traded at $2.08, 31.6% below their 52-week high. Over the past year the stock is up 344.6%. Net profit margin is -100.6%, below the peer median of 5.3%. Revenue grew 1556.8% year over year.

Market Cap
$377M
Shares Out
181.1M
EPS (TTM)
$0.23
P/E Ratio
9.04
P/S Ratio
3.45
P/B Ratio
1.62
Dividend / Share
Dividend Yield
52-Week High
$3.04
52-Week Low
$0.44
Volume
55,563
Avg Vol (3m)
76,072.794

Performance

1W
-6.73%
1M
+5.58%
3M
-5.02%
6M
-18.43%
YTD
+109.23%
1Y
+344.63%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
50.02
SMA (50)
$2.14
SMA (200)
$1.94
Price vs SMA50
-2.72%
Price vs SMA200
+7.15%
ATR (14)
$0.11

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$109M
Net Income
$-110M
Gross Margin
Operating Margin
-107.2%
Net Margin
-100.6%
Return on Equity
-47.3%
Return on Assets
-38.3%
Current Ratio
8.28
Debt / Equity
0.04
Revenue Growth (YoY)
+1556.8%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.28 2026-08-12
Q1 2026 $-0.11 2026-05-13
FY 2025 $-0.14 2026-03-12
Q3 2025 $0.11 2025-11-13
Q2 2026 $0.51 2026-08-12
Q1 2026 $0.89 2026-05-13

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

IPSC vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
3.45 / 19.49 med
-82% discount
Net margin vs peers
-100.6% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.